Related Experiment Videos
[Physiopathological basis of the treatment of heart failure]
C Vinsonneau1, J B Su, S Benacerraf
1Fédération de cardiologie, hôpital Henri-Mondor, Creteil.
Insights
Modern cardiac failure treatment focuses on blocking vasoconstriction with drugs like angiotensin converting enzyme inhibitors and betablockers. Future strategies may involve stimulating vasodilator systems and early detection of myocardial ischemia to prevent heart muscle loss.
Area of Science:
- Cardiology
- Cardiovascular Physiology
Context:
- Cardiac failure presentation has evolved due to therapeutic advances.
- Myocardial ischemia is now the primary cause of cardiac failure.
- Modern treatment strategies leverage understanding of cardiac physiology.
Purpose:
- To outline the physiopathological basis of modern cardiac failure treatment.
- To highlight the role of vasodilatation and vasoconstriction blocking agents.
- To explore future therapeutic avenues and prevention strategies.
Summary:
- Current cardiac failure management centers on angiotensin converting enzyme inhibitors and betablockers, targeting vasodilatation and vasoconstrictive systems.
- The myocardium's function as a pump, muscle, and its oxygen supply via coronary circulation are key physiological considerations.
- Future treatments may involve stimulating vasodilator systems and early detection of ischemia to preserve cardiac myocytes.
Impact:
- Advances in treatment have shifted the clinical presentation of cardiac failure.
- Early detection and management of ischemia are crucial for slowing disease progression.
- Preventing cardiac failure necessitates educating cardiologists on managing predisposing factors.
Abstract:
Therapeutic advances have changed the mode of presentation of cardiac failure over the last decades: the main cause, nowadays, is myocardial ischaemia. The modern treatment of cardiac failure is based on relatively simple physiopathological mechanisms which take into account the different aspects of cardiac physiology: a pump, a muscle, a coronary circulation supplying oxygen to the myocardium, an automatic contraction. The concept of vasodilatation and the blocking of vasoconstrictive systems introduced during the 70s is the basis of modern treatment of cardiac failure which involves angiotensin converting enzyme inhibitors and, increasingly, betablockers. In the near future, with earlier treatment of cardiac failure, the stimulation of vasodilator systems could become a new therapeutic strategy. Early detection of ischaemia and its complications with the aim of limiting the loss of cardiac myocytes is a priority for slowing the progression of cardiac failure. The prevention of cardiac failure also depends on educating cardiologists to treat rapidly the factors predisposing to or prolonging episodes of even mild cardiac failure.